Cargando…

Epigenetic histone modulation contributes to improvements in inflammatory bowel disease via EBI3

Ulcerative colitis (UC) is characterized by relapsing–remitting inflammatory episodes paralleled by varying cytokine levels, suggesting that switching epigenetic processes might be involved. However, the epigenetic impact on cytokine levels in colitis is mostly unexplored. The heterodimeric interleu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wetzel, Alexandra, Scholtka, Bettina, Gerecke, Christian, Kleuser, Burkhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658076/
https://www.ncbi.nlm.nih.gov/pubmed/31955243
http://dx.doi.org/10.1007/s00018-020-03451-9
_version_ 1783608588271353856
author Wetzel, Alexandra
Scholtka, Bettina
Gerecke, Christian
Kleuser, Burkhard
author_facet Wetzel, Alexandra
Scholtka, Bettina
Gerecke, Christian
Kleuser, Burkhard
author_sort Wetzel, Alexandra
collection PubMed
description Ulcerative colitis (UC) is characterized by relapsing–remitting inflammatory episodes paralleled by varying cytokine levels, suggesting that switching epigenetic processes might be involved. However, the epigenetic impact on cytokine levels in colitis is mostly unexplored. The heterodimeric interleukin (IL)-12 cytokine family have various functions in both pro- and anti-inflammatory processes. The family member IL-35 (EBI3/IL-12p35) was recently reported to play an anti-inflammatory role in UC. Therefore, we aimed to investigate a possible epigenetic regulation of the IL-35 subunits in vitro and in vivo, and to examine the epigenetic targeting of EBI3 expression as a therapeutic option for UC. Exposure to either the pro-inflammatory TNFα or to histone deacetylase inhibitors (HDACi) significantly increased EBI3 expression in Human Colon Epithelial Cells (HCEC) generated from healthy tissue. When applied in combination, a drastic upregulation of EBI3 expression occurred, suggesting a synergistic mechanism. Consequently, IL-35 was increased as well. In vivo, the intestines of HDACi-treated wild-type mice exhibited reduced pathological signs of colitis compared to non-treated colitic mice. However, the improvement by HDACi treatment was completely lost in Ebi3-deficient mice (Ebi3(−/−)). In fact, HDACi appeared to exacerbate the disease phenotype in Ebi3(−/−). In conclusion, our results reveal that under inflammatory conditions, EBI3 is upregulated by the epigenetic mechanism of histone acetylation. The in vivo data show that the deficiency of EBI3 plays a key role in colitis manifestation. Concordantly, our data suggest that conditions promoting histone acetylation, such as upon HDACi application, improve colitis by a mechanism involving the local formation of the anti-inflammatory cytokine IL-35. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00018-020-03451-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7658076
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-76580762020-11-12 Epigenetic histone modulation contributes to improvements in inflammatory bowel disease via EBI3 Wetzel, Alexandra Scholtka, Bettina Gerecke, Christian Kleuser, Burkhard Cell Mol Life Sci Original Article Ulcerative colitis (UC) is characterized by relapsing–remitting inflammatory episodes paralleled by varying cytokine levels, suggesting that switching epigenetic processes might be involved. However, the epigenetic impact on cytokine levels in colitis is mostly unexplored. The heterodimeric interleukin (IL)-12 cytokine family have various functions in both pro- and anti-inflammatory processes. The family member IL-35 (EBI3/IL-12p35) was recently reported to play an anti-inflammatory role in UC. Therefore, we aimed to investigate a possible epigenetic regulation of the IL-35 subunits in vitro and in vivo, and to examine the epigenetic targeting of EBI3 expression as a therapeutic option for UC. Exposure to either the pro-inflammatory TNFα or to histone deacetylase inhibitors (HDACi) significantly increased EBI3 expression in Human Colon Epithelial Cells (HCEC) generated from healthy tissue. When applied in combination, a drastic upregulation of EBI3 expression occurred, suggesting a synergistic mechanism. Consequently, IL-35 was increased as well. In vivo, the intestines of HDACi-treated wild-type mice exhibited reduced pathological signs of colitis compared to non-treated colitic mice. However, the improvement by HDACi treatment was completely lost in Ebi3-deficient mice (Ebi3(−/−)). In fact, HDACi appeared to exacerbate the disease phenotype in Ebi3(−/−). In conclusion, our results reveal that under inflammatory conditions, EBI3 is upregulated by the epigenetic mechanism of histone acetylation. The in vivo data show that the deficiency of EBI3 plays a key role in colitis manifestation. Concordantly, our data suggest that conditions promoting histone acetylation, such as upon HDACi application, improve colitis by a mechanism involving the local formation of the anti-inflammatory cytokine IL-35. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00018-020-03451-9) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-01-18 2020 /pmc/articles/PMC7658076/ /pubmed/31955243 http://dx.doi.org/10.1007/s00018-020-03451-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
Wetzel, Alexandra
Scholtka, Bettina
Gerecke, Christian
Kleuser, Burkhard
Epigenetic histone modulation contributes to improvements in inflammatory bowel disease via EBI3
title Epigenetic histone modulation contributes to improvements in inflammatory bowel disease via EBI3
title_full Epigenetic histone modulation contributes to improvements in inflammatory bowel disease via EBI3
title_fullStr Epigenetic histone modulation contributes to improvements in inflammatory bowel disease via EBI3
title_full_unstemmed Epigenetic histone modulation contributes to improvements in inflammatory bowel disease via EBI3
title_short Epigenetic histone modulation contributes to improvements in inflammatory bowel disease via EBI3
title_sort epigenetic histone modulation contributes to improvements in inflammatory bowel disease via ebi3
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658076/
https://www.ncbi.nlm.nih.gov/pubmed/31955243
http://dx.doi.org/10.1007/s00018-020-03451-9
work_keys_str_mv AT wetzelalexandra epigenetichistonemodulationcontributestoimprovementsininflammatoryboweldiseaseviaebi3
AT scholtkabettina epigenetichistonemodulationcontributestoimprovementsininflammatoryboweldiseaseviaebi3
AT gereckechristian epigenetichistonemodulationcontributestoimprovementsininflammatoryboweldiseaseviaebi3
AT kleuserburkhard epigenetichistonemodulationcontributestoimprovementsininflammatoryboweldiseaseviaebi3